Lexaria Bioscience Corp

NASDAQ:LEXX 4:00:00 PM EDT

3.52

-0.04 (-1.12%)

5:24:22 PM EDT: $3.48 -0.04 (-1.14%)

Market Cap (Intraday)	55.65M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.18 Million
Adjusted EPS	-$0.11

See more estimates

10-Day MA	$3.41
50-Day MA	$3.20
200-Day MA	$2.72

See more pivots

Lexaria Bioscience Corp Stock, NASDAQ:LEXX

740 McCurdy Road, Suite 100, Kelowna, British Columbia V1X 2P7

Canada

Phone: +1.250.765.6424

Number of Employees: 5

http://www.lexariabioscience.com

Description

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. Its products can be used with APIs fat-soluble vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) pain medications, hormones, phosphodiesterase inhibitors, antivirals, nicotine and its analogs, and all cannabinoids including tetrahydrocannabinol (THC) for therapeutic indications, as well as hypertension, SARS-CoV-2/COVID-19, and HIV/AIDS. It operates through the following segments: IP Licensing, B2B Product, Research and Development, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.